Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Both injections carry the normal risks of any injectable, but the bigger concern with unlicensed products is that complications are harder to predict and harder to treat
The current lack of very effective mechanisms and tools is intimately related to the complex pathogenesis of impaired organs
The differences come down to regulation, cost, and how you access them
In PsA, the phase 3b TOGETHER-PsA trial (NCT06588296) assesses the combined use of ixekizumab and tirzepatide in patients with active disease and concomitant overweight or obesity, while the phase 4 TOGETHER AMPLIFY-PsA study (NCT06864026) examines the effectiveness of adding tirzepatide to ixekizumab in clinical practice over 12 months
US$ 24.93
US$ 22.18
US$ 27.08
US$ 28.79
US$ 26.89
